[Federal Register Volume 64, Number 27 (Wednesday, February 10, 1999)]
[Notices]
[Page 6681]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-3159]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated December 12, 1998, and published in the Federal 
Register on December 11, 1998, (63 FR 68473), Glaxo Welcome Inc., Attn: 
Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, 
North Carolina 27597-2309, made application to the Drug Enforcement 
Administration to be registered as an importer of remifentanil (9739), 
a basic class of controlled substance listed in Schedule II.
    The remifentanil is being imported for the production of Ultiva 
dosage forms and for research and new product development.
    No comments or objections have been received. DEA has considered 
the factors in Title 21, United States Code, Section 823(a) and 
determined that the registration of Glaxo Welcome Inc. to import 
remifentanil is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. DEA has investigated 
Glaxo Welcome Inc. on a regular basis to ensure that the company's 
continued registration is consistent with the public interest. These 
investigations have included inspection and testing of the company's 
physical security systems, audit of the company's records, verification 
of the company's compliance with state and local laws, and a review of 
the company's background and history. Therefore, pursuant to Section 
1008(a) of the Controlled Substances Import and Export Act and in 
accordance with Title 21, Code of Federal Regulations, Section 1301.34, 
the above firm is granted registration as an importer of the basic 
class of controlled substance listed above.

    Dated: February 2, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-3159 Filed 2-9-99; 8:45 am]
BILLING CODE 4410-09-M